1-3 of 3
Keywords: Glycoprotein IIb/IIIa inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients: A Double-Blind Randomized Study

Available to Purchase
Subject Area:
Cardiovascular System , Pharmacology
Pietro Di Pasquale, Sergio Cannizzaro, Sebastiano Scalzo, Francesco Giambanco, Giuseppe Tricoli, Sergio Fasullo, Salvatore Paterna
Journal: Heart Drug
Heart Drug (2005) 5 (4): 187–192.
https://doi.org/10.1159/000089598
Published Online: 22 December 2005
... underwent a percutaneous coronary intervention (PCI) for non-ST elevation myocardial infarction. All patients received a glycoprotein IIb/IIIa inhibitor and were randomized in double-blind fashion to ticlopidine (500 mg/day) + aspirin or clopidogrel (75 mg/day) + aspirin before PCI. After 48– 72 h, PCI...
View article titled, Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients: A Double-Blind Randomized Study
Open the PDF for Comparison of Ticlopidine and Aspirin versus Clopidogrel and Aspirin after Percutaneous Coronary Interventions in High-Risk Patients: A Double-Blind Randomized Study in another window
Journal Articles

Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

Available to Purchase
Subject Area:
Cardiovascular System , Pharmacology
M.S. Spence, T.P. Mathew, G. Manoharan, J.W. Riddell, A.A.J. Adgey
Journal: Heart Drug
Heart Drug (2001) 1 (2): 103–109.
https://doi.org/10.1159/000048945
Published Online: 17 November 2004
... to coronary intervention. The benefits particularly relate to high-risk patients. In contrast oral GP IIb/IIIa inhibitors have not been shown to improve outcomes in ACS patients. Review Heart Drug 2001;1:103 109 Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes M.S. Spence T.P. Mathew G. Manoharan...
View article titled, Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Open the PDF for Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes in another window
Journal Articles

Variable Interindividual Responses to Antiplatelet Therapies – Do They Exist, Can We Measure Them, and Are They Clinically Relevant? : Insights from the GOLD (AU – Assessing Ultegra) Trial

Available to Purchase
Subject Area:
Cardiovascular System , Pharmacology
Eric van de Graaff, Steven R. Steinhubl
Journal: Heart Drug
Heart Drug (2000) 1 (1): 35–43.
https://doi.org/10.1159/000022709
Published Online: 12 March 2001
... to the antiplatelet effects of aspirin, and have developed substantial evidence to support this theory. The thienopyridines ticlopidine and clopidogrel and the glycoprotein IIb/IIIa inhibitors also exhibit substantial interpatient variability in the level of platelet inhibition they achieve. There are several...
View article titled, Variable Interindividual Responses to Antiplatelet Therapies – Do They Exist, Can We Measure Them, and Are They Clinically Relevant? : Insights from the GOLD (AU – Assessing Ultegra) Trial
Open the PDF for Variable Interindividual Responses to Antiplatelet Therapies – Do They Exist, Can We Measure Them, and Are They Clinically Relevant? : Insights from the GOLD (AU – Assessing Ultegra) Trial in another window